Literature DB >> 21129423

Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy.

Anupa R Menjoge1, Amber L Rinderknecht, Raghavendra S Navath, Masoud Faridnia, Chong J Kim, Roberto Romero, Richard K Miller, Rangaramanujam M Kannan.   

Abstract

Dendrimers offer significant potential as nanocarriers for targeted delivery of drugs and imaging agents. The objectives of this study were to evaluate the transplacental transport, kinetics and biodistribution of PAMAM dendrimers ex-vivo across the human placenta in comparison with antipyrine, a freely diffusible molecule, using dually perfused re-circulating term human placental lobules. The purpose of this study is to determine if dendrimers as drug carriers can be used to design drug delivery systems directed at selectively treating either the mother or the fetus. The transplacental transfers of fluorescently (Alexa 488) tagged PAMAM dendrimer (16 kDa) and antipyrine (188 Da) from maternal to fetal circulation were measured using HPLC/dual UV and fluorescent detector (sensitivity of 10 ng/mL for dendrimer and 100 ng/mL for antipyrine respectively). C(max) for the dendrimer-Alexa (DA) in maternal perfusate (T(max)=15 min) was 18 times higher than in the fetal perfusate and never equilibrated with the maternal perfusate during 5.5 h of perfusion (n=4). DA exhibited a measurable but low transplacental transport of 2.26±0.12 μg/mL during 5.5h, where the mean transplacental transfer was 0.84±0.11% of the total maternal concentration and the feto-maternal ratio as percent was 0.073%±0.02. The biochemical and physiological analysis of the placentae perfused with DA demonstrated normal function throughout the perfusion. The immunofluorescence histochemistry confirmed that the biodistribution of DA in perfused placenta was sparsely dispersed, and when noted was principally seen in the inter-villous spaces and outer rim of the villous branches. In a few cases, DA was found internalized and localized in nuclei and cytoplasm of syncytiotrophoblast and inside the villous core; however, DA was mostly absent from the villous capillaries. In conclusion, the PAMAM dendrimers exhibited a low rate of transfer from maternal to the fetal side across the perfused human placenta, which is similar to other investigations of large macromolecules, e.g., IgG. These overall findings suggest that entry of drugs conjugated to polymers, i.e., dendrimers, would be limited in their transfer across the human placenta when compared to smaller drug molecules alone, suggesting novel methods for selectively delivering therapeutics to the pregnant woman without significant transfer to the fetus, especially since the half life of the dendrimer in blood is relatively short.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21129423      PMCID: PMC3095460          DOI: 10.1016/j.jconrel.2010.11.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  44 in total

Review 1.  Transplacental transport of nanomaterials.

Authors:  Margaret Saunders
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2009 Nov-Dec

Review 2.  Nanotechnology and the transdermal route: A state of the art review and critical appraisal.

Authors:  Gregor Cevc; Ulrich Vierl
Journal:  J Control Release       Date:  2009-10-20       Impact factor: 9.776

3.  Receptor-mediated uptake and transport of macromolecules in the human placenta.

Authors:  Henning Schneider; Richard K Miller
Journal:  Int J Dev Biol       Date:  2010       Impact factor: 2.203

4.  Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates.

Authors:  Anupa R Menjoge; Raghavendra S Navath; Abbas Asad; Sujatha Kannan; Chong J Kim; Roberto Romero; Rangaramanujam M Kannan
Journal:  Biomaterials       Date:  2010-03-25       Impact factor: 12.479

5.  Transfer across the perfused human placenta of antipyrine, sodium and leucine.

Authors:  H Schneider; M Panigel; J Dancis
Journal:  Am J Obstet Gynecol       Date:  1972-11-15       Impact factor: 8.661

6.  Osmosis across term human placental membranes.

Authors:  A E Seeds
Journal:  Am J Physiol       Date:  1970-08

7.  Absorption of peroxidase-conjugated immunoglobulin G by human placenta: an in vitro study.

Authors:  B F King
Journal:  Placenta       Date:  1982 Oct-Dec       Impact factor: 3.481

8.  Permeability of fetal membranes to calcium and magnesium: possible role in preterm labour.

Authors:  A Lemancewicz; H Laudańska; T Laudański; A Karpiuk; S Batra
Journal:  Hum Reprod       Date:  2000-09       Impact factor: 6.918

9.  Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery.

Authors:  Yunus E Kurtoglu; Raghavendra S Navath; Bing Wang; Sujatha Kannan; Robert Romero; Rangaramanujam M Kannan
Journal:  Biomaterials       Date:  2009-01-25       Impact factor: 12.479

10.  3H dendrimer nanoparticle organ/tumor distribution.

Authors:  Shraddha S Nigavekar; Lok Yun Sung; Mikel Llanes; Areej El-Jawahri; Theodore S Lawrence; Christopher W Becker; Lajos Balogh; Mohamed K Khan
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

View more
  31 in total

1.  Polymer size affects biodistribution and placental accumulation of the drug delivery biopolymer elastin-like polypeptide in a rodent pregnancy model.

Authors:  Marija Kuna; Jamarius P Waller; Omar C Logue; Gene L Bidwell
Journal:  Placenta       Date:  2018-10-20       Impact factor: 3.481

2.  Is an episode of suspected preterm labor that subsequently leads to a term delivery benign?

Authors:  Roberto Romero; Offer Erez; Eli Maymon; Percy Pacora
Journal:  Am J Obstet Gynecol       Date:  2017-02       Impact factor: 8.661

3.  A polypeptide drug carrier for maternal delivery and prevention of fetal exposure.

Authors:  Eric M George; Huiling Liu; Grant G Robinson; Gene L Bidwell
Journal:  J Drug Target       Date:  2014-08-22       Impact factor: 5.121

Review 4.  The Placental Barrier: the Gate and the Fate in Drug Distribution.

Authors:  Nino Tetro; Sonia Moushaev; Miriam Rubinchik-Stern; Sara Eyal
Journal:  Pharm Res       Date:  2018-02-23       Impact factor: 4.200

5.  Polymeric conjugates for drug delivery.

Authors:  Nate Larson; Hamidreza Ghandehari
Journal:  Chem Mater       Date:  2012-01-04       Impact factor: 9.811

6.  Kinetics of silica nanoparticles in the human placenta.

Authors:  Marie Sønnegaard Poulsen; Tina Mose; Lisa Leth Maroun; Line Mathiesen; Lisbeth Ehlert Knudsen; Erik Rytting
Journal:  Nanotoxicology       Date:  2013-07-01       Impact factor: 5.913

7.  Disposition of intravenously or orally administered silver nanoparticles in pregnant rats and the effect on the biochemical profile in urine.

Authors:  Timothy R Fennell; Ninell P Mortensen; Sherry R Black; Rodney W Snyder; Keith E Levine; Eric Poitras; James M Harrington; Christopher J Wingard; Nathan A Holland; Wimal Pathmasiri; Susan C J Sumner
Journal:  J Appl Toxicol       Date:  2016-10-03       Impact factor: 3.446

Review 8.  Placental control of drug delivery.

Authors:  Sanaalarab Al-Enazy; Shariq Ali; Norah Albekairi; Marwa El-Tawil; Erik Rytting
Journal:  Adv Drug Deliv Rev       Date:  2016-08-12       Impact factor: 15.470

9.  Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Authors:  John V Ilekis; Ekaterini Tsilou; Susan Fisher; Vikki M Abrahams; Michael J Soares; James C Cross; Stacy Zamudio; Nicholas P Illsley; Leslie Myatt; Christine Colvis; Maged M Costantine; David M Haas; Yoel Sadovsky; Carl Weiner; Erik Rytting; Gene Bidwell
Journal:  Am J Obstet Gynecol       Date:  2016-03-10       Impact factor: 8.661

10.  Evidence of oral translocation of anionic G6.5 dendrimers in mice.

Authors:  Giridhar Thiagarajan; Shraddha Sadekar; Khaled Greish; Abhijit Ray; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2013-01-25       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.